title: Angiogenic potential of ductal carcinoma in situ (DCIS) of human breast.
abstract: OBJECTIVE
  Comedo carcinoma is generally regarded as the subtype of ductal carcinoma in situ (DCIS) most likely to progress to invasive carcinoma. Increased angiogenesis could be associated with an enhanced risk of progression and might therefore be a marker of poor prognosis, as can be demonstrated for invasive breast tumours. Therefore, the present study investigates the correlations between the expression of oncoproteins (HER2, HER1/EGFR), angiogenic growth factors (VEGF and PD-ECGF/TP) and microvessel density (MVD) in DCIS.
  
  
  RESULTS
  Forty-six breast cancer specimens of DCIS were tested immunohistochemically for the expression of angiogenic factors and oncoproteins. Different vascular distribution patterns of DCIS were examined semiquantitatively. Our results showed a significantly inverse correlation between HER1/EGFR and comedo-type DCIS (P = 0.048), but HER1/EGFR expression seemed to be independent of HER2 overexpression. VEGF expression was significantly associated with endoglin expression (P = 0.031) and the cuffing phenomenon (P = 0.017).
  
  
  CONCLUSIONS
  The significantly inverse correlation between HER1/EGFR and comedo-type DCIS and the observation that VEGF and the other angiogenic factors tested are independent of HER2 overexpression, suggest that progression of comedo-type DCIS and angiogenesis in breast carcinoma are not regulated via the HER1/EGFR or HER2 pathway.
authors.affiliation: Institute of Pathology, Private Medical School Salzburg, Austria. georgia.vogl@uibk.ac.at
authors.forename: G
authors.initials: G
authors.lastname: Vogl
authors.forename: O
authors.initials: O
authors.lastname: Dietze
authors.forename: C
authors.initials: C
authors.lastname: Hauser-Kronberger
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000098:blood supply* / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D002285:Carcinoma, Intraductal, Noninfiltrating / Q000098:blood supply* / Q000201:enzymology / Q000378:metabolism* / Q000473:pathology; D016009:Chi-Square Distribution; D066246:ErbB Receptors / Q000378:metabolism; D005260:Female; D018773:Genes, erbB-1; D018734:Genes, erbB-2; D006801:Humans; D007150:Immunohistochemistry; D008833:Microcirculation / Q000473:pathology; D008875:Middle Aged; D009389:Neovascularization, Pathologic; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D012189:Retrospective Studies; D013939:Thymidine Phosphorylase / Q000378:metabolism; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D066246:ErbB Receptors; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D013939:Thymidine Phosphorylase; D042461:Vascular Endothelial Growth Factor A